Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors

Podcast featuring Jean-Marie Cuillerot, Chief Medical Officer at Kainova Therapeutics – Closing the gap on rare diseases in 2026

Understanding the US FDA’s Special Designations and Approval Pathways

Recognizing the challenges of drug development, the US FDA has established several special designations and…